Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007)

Francesco Grossi, Gianpiero Fasola, Ciro Rossetto, Riccardo Spizzo, Stefano Meduri, Angela Sibau, Enrico Vigevani, Salvatore Tumolo, Gianna Adami, Cosimo Sacco, Leonardo Recchia, Simona Rizzato, Tino Ceschia, Ornella Belvedere

Research output: Contribution to journalArticlepeer-review

Abstract

This study was designed to evaluate the activity and tolerability of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer (NSCLC). Eligibility included recurrent or progressive NSCLC, previous chemotherapy, age ≥18 years, ECOG PS ≤2. Treatment consisted of irinotecan (160 mg/m2 i.v.), followed by docetaxel (65 mg/m2 i.v.) on day 1 of a 21-day cycle, for a maximum of 6 cycles. Forty patients were enrolled. Median age was 60 years and median ECOG PS was 1. All patients were evaluable for toxicity and 31 (78%) were evaluable for response. A total of 125 cycles was administered (median, 3; range, 1-6). Most common grade 3-4 toxicities were neutropenia (62%), neutropenic fever (22%), and diarrhea (32%). Response rate was 10%; a further 40% of patients achieved stable disease. All responses were observed in patients with ECOG PS ≤1, age

Original languageEnglish
Pages (from-to)89-92
Number of pages4
JournalLung Cancer
Volume52
Issue number1
DOIs
Publication statusPublished - Apr 2006

Keywords

  • Docetaxel
  • Irinotecan
  • Non-small cell lung cancer
  • Phase II study
  • Second line chemotherapy

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007)'. Together they form a unique fingerprint.

Cite this